Galderma Group AG (CH:GALD)
:GALD
GALD Stock Chart & Stats
CHF153.40
-CHF8.02(-7.15%)
At close: 4:00 PM EST
CHF153.40
-CHF8.02(-7.15%)
Day’s Range― - ―
52-Week RangeCHF72.70 - CHF170.10
Previous CloseN/A
Volume230.69K
Average Volume (3M)337.59K
Market Cap
CHF36.02B
Enterprise ValueCHF38.66B
Total Cash (Recent Filing)CHF780.00M
Total Debt (Recent Filing)CHF2.75B
Price to Earnings (P/E)28.6
Beta0.73
Next Earnings
Jul 23, 2026EPS Estimate
1.85Next Dividend Ex-DateN/A
Dividend Yield0.09%
Share Statistics
EPS (TTM)1.60
Shares Outstanding237,897,630
10 Day Avg. Volume210,266
30 Day Avg. Volume337,589
Financial Highlights & Ratios
PEG Ratio0.61
Price to Book (P/B)4.71
Price to Sales (P/S)8.88
P/FCF Ratio37.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF183.09Price Target Upside19.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)4.59
Revenue Forecast (FY)CHF6.26B
Bulls Say, Bears Say
Bulls Say
Clinical DataClinical results for Nemluvio demonstrated rapid, meaningful reductions in skin lesions and itch in pediatric patients, with pharmacokinetic exposure matching older patients and supporting consistent dosing and strong adoption potential in children with moderate-to-severe atopic dermatitis.
Commercial PotentialAnalysts identify Nemluvio as a standout revenue driver after a rapid sales ramp, with expectations for substantially higher peak sales and potential management upgrades to guidance, indicating significant upside to consensus forecasts.
Product Approvals And InnovationFDA approval of Restylane Contour for temple hollowing, combined with a patent-pending dual-layer injection technique, broadens the injectable portfolio and addresses demand linked to medication-driven facial volume loss, supporting market share gains in aesthetics.
Bears Say
Derma Skincare PerformanceUnderperformance in the Derma Skincare division restrained overall company growth, creating a drag on reported results despite stronger performance in other segments.
Profitability PressureA modest downturn in Derma Skincare sales could limit margin expansion and strain profitability, offsetting gains from other divisions and complicating efforts to improve overall earnings.
Revenue Concentration RiskWeakness in the skincare segment increases reliance on injectable aesthetics and biologics for growth, heightening sensitivity to execution risks and competitive dynamics in those businesses.
Galderma Group AG News
GALD FAQ
What was Galderma Group AG’s price range in the past 12 months?
Galderma Group AG lowest stock price was CHF72.70 and its highest was CHF170.10 in the past 12 months.
What is Galderma Group AG’s market cap?
Galderma Group AG’s market cap is CHF36.02B.
When is Galderma Group AG’s upcoming earnings report date?
Galderma Group AG’s upcoming earnings report date is Jul 23, 2026 which is in 112 days.
How were Galderma Group AG’s earnings last quarter?
Galderma Group AG released its earnings results on Mar 05, 2026. The company reported CHF1.596 earnings per share for the quarter, beating the consensus estimate of CHF1.239 by CHF0.357.
Is Galderma Group AG overvalued?
According to Wall Street analysts Galderma Group AG’s price is currently Undervalued.
Does Galderma Group AG pay dividends?
Galderma Group AG pays a Notavailable dividend of CHF0.15 which represents an annual dividend yield of 0.09%. See more information on Galderma Group AG dividends here
What is Galderma Group AG’s EPS estimate?
Galderma Group AG’s EPS estimate is 1.85.
How many shares outstanding does Galderma Group AG have?
Galderma Group AG has 237,897,630 shares outstanding.
What happened to Galderma Group AG’s price movement after its last earnings report?
Galderma Group AG reported an EPS of CHF1.596 in its last earnings report, beating expectations of CHF1.239. Following the earnings report the stock price went up 6.975%.
Which hedge fund is a major shareholder of Galderma Group AG?
Currently, no hedge funds are holding shares in CH:GALD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Galderma Group AG
Galderma Group AG is engaged in cosmetic industry. Its segment includes Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology.
GALD Stock 12 Month Forecast
Average Price Target
CHF183.09
▲(19.35% Upside)
Technical Analysis
Options Prices
Currently, No data available
---